Treatment explainer · Labels read August 11, 2026

Veozah alternatives: every non-hormonal hot flash option, and what each one costs you in bloodwork

By Iacob Pastina. Every clinical figure below is read from a primary source: the two drugs' own FDA structured product labels via openFDA, and the ClinicalTrials.gov registry record. No figure here comes from a press release or a news summary.

Medical disclaimer: this page is independent editorial information, not medical advice. Hot flashes, liver risk and drug interactions are individual. Talk to a licensed clinician before starting, stopping or changing any treatment.

What are the FDA-approved non-hormonal treatments for hot flashes?

Two, both of them neurokinin receptor antagonists, both of them taken by mouth. They work on the brain's temperature-control signalling rather than on estrogen, which is why they are the option for women who cannot or will not take hormones. The class is narrow and the two members are not interchangeable.

Read directly from the FDA structured product labels on August 11, 2026: Veozah label (openFDA) and Lynkuet label (openFDA). Both label records carried a data timestamp of August 10, 2026.

Which one has the lighter monitoring burden?

Lynkuet, by a wide margin, and this is the comparison that actually changes what a year of treatment looks like. Count the blood draws each label requires in the first nine months: Veozah asks for a baseline panel, then months one, two and three, then month six, then month nine. Six visits. Lynkuet asks for a baseline panel and one follow-up at three months. Two visits.

That gap is a cost and an adherence problem before it is a safety question. Four extra lab appointments inside nine months is four extra copays, four extra half-days, and four more chances to fall off treatment. It is also the reason a telehealth provider cannot honestly sell either drug off a questionnaire alone, and a reasonable thing to ask about before you pay for an intake.

The trade-off runs the other way on the warning list. Veozah's single hepatotoxicity risk is boxed and heavily monitored. Lynkuet spreads a longer list across next-day impairment (its label reports nervous system effects in 11.9% of patients on drug against 3.5% on placebo across the three OASIS trials), liver enzyme elevations, pregnancy loss, and seizure. Fewer blood draws, more things to read about.

What about hormone therapy as the alternative?

For most women with moderate-to-severe vasomotor symptoms and no contraindication, estrogen remains the more effective option, and the FDA removed the class-wide boxed warning from hormone therapy labels in a process announced in November 2025 with label changes approved in February 2026. The non-hormonal drugs exist for the women who cannot take estrogen, or who have decided not to. If you are still weighing the two routes, start with what the black box warning change actually did, then what HRT costs and our scored provider comparison. If you are still in the run-up rather than post-menopause, the perimenopause hub is the better starting point.

What is actually in the non-hormonal pipeline?

Less than the coverage suggests. On August 10, 2026 a run of trade stories treated AbCellera's ABCL635 as a late-stage menopause drug. The trial registry describes something materially narrower, and the gap is large enough to be worth setting out line by line.

A large hot-flash reduction figure circulated with that coverage. We are not repeating it as fact, because we could not reach a primary source for it: AbCellera's investor site returned an HTTP 403 behind a bot challenge, and a full-text search of SEC EDGAR for the compound returned no hits. [Reported] and unconfirmed is where that number stands here. What the registry does show is that no hot-flash endpoint in this study is a primary outcome, so a headline percentage would be describing a secondary measure on a single dose in a safety trial.

For scale, use Veozah as the reference class. A drug in this space needed Phase 3 topline results and an FDA action date before approval came into view. ABCL635 has neither, and its own estimated primary completion is February 2027. Anyone with hot flashes today is choosing between the two approved drugs and hormone therapy, not waiting for this one.

Common questions

What are the alternatives to Veozah for hot flashes?

There is one other FDA-approved non-hormonal drug for moderate-to-severe menopausal hot flashes: Lynkuet (elinzanetant), a neurokinin 1 and 3 receptor antagonist from Bayer, dosed at 120 mg (two 60 mg capsules) orally once daily at bedtime. Veozah (fezolinetant) is a neurokinin 3 antagonist from Astellas, dosed at one 45 mg tablet once daily. The other route is hormone therapy itself, which is a different class with a different risk profile. Everything else marketed for hot flashes, including compounded and supplement products, is not FDA-approved for this indication.

Why does Veozah have a boxed warning and Lynkuet does not?

Veozah carries a boxed warning for hepatotoxicity, added to its label in December 2024 after liver injury was reported in the postmarketing setting. Lynkuet's label has no boxed warning, but it does carry warnings for hepatic transaminase elevations, central nervous system depressant effects and daytime impairment, risk of pregnancy loss, and risk of seizure. The seizure warning is recent: the label records it as a major change in August 2026. A missing boxed warning is not the same thing as a clean safety profile, and neither drug is monitoring-free.

How much blood testing does each drug require?

Veozah's label requires hepatic laboratory tests before you start, then monthly for the first three months, then at six months and at nine months. That is a baseline plus five follow-up draws inside the first nine months. Lynkuet's label requires baseline hepatic tests and one follow-up evaluation three months after starting, so a baseline plus one. Both labels say not to start the drug if ALT or AST is at or above two times the upper limit of normal, or if total bilirubin is at or above two times the upper limit of normal.

Is ABCL635 a new menopause pill that cuts hot flashes by 83%?

No, and the framing is wrong in three ways. Per the ClinicalTrials.gov record for NCT07118891, ABCL635 is a first-in-human Phase 1/2 study, not a late-stage one. It is a biological given by subcutaneous injection, not a pill. And every hot-flash measure in it, including HFM-S, VMSM-S frequency and severity, and MENQOL, sits as a secondary outcome in Part C on a single dose, while all four primary outcomes are safety measures. Estimated primary completion is February 2027. The percentage figure circulating in trade coverage could not be traced to any primary source we were able to reach.

Can I get a non-hormonal hot flash prescription through telehealth?

Some menopause telehealth providers prescribe non-hormonal options alongside hormone therapy, but both approved drugs require baseline liver bloodwork before the first dose, which means the provider has to order labs rather than prescribe off a questionnaire. Check what a provider's intake actually includes before paying. Our provider comparison scores each one on clinical depth and price transparency.

We take no money for rankings and no payment for placement. Read our editorial policy and affiliate disclosure.